Baseline data and the effect of phase II medications on outcome variables at week 4–5
| Outcome variable | Placebo | Beclomethasone | p value3-150 |
|---|---|---|---|
| Cough frequency (number in 24 hours) | |||
| Baseline, geometric mean (SD) | 27 (4.2) | 63 (2.3) | |
| % change, (95% CI) | −45 (−74, 18) | −72 (−88, −33) | 0.82 |
| Symptom score (parent completed) | |||
| Baseline, median (IQR) | 3.4 (3.7) | 3.5 (4.3) | |
| Change, mean (95% CI) | −1.5 (−2.4, −0.5) | −0.9 (−1.7, −0.1) | 0.45 |
| Symptom score (child completed) | |||
| Baseline, median (IQR) | 2.7 (4.1) | 3 (4.2) | |
| Change, mean (95% CI) | −1.5 (−2.5, −0.6) | −0.9 (−1.7, −0.1) | 0.28 |
| Log10 Cth (μmol) | |||
| Baseline, median (IQR) | 0.99 (1.1) | 0.99 (1.2) | |
| Change, mean (95% CI) | 0.06 (−0.17, 0.3) | −0.17 (−0.44, 0.1) | 0.08 |
| Log10 C5 (μmol) | |||
| Baseline, median (IQR) | 1.29 (1.2) | 1.59 (0.75) | |
| Change, mean (95% CI) | 0.08 (−0.2, 0.36) | −0.01 (−0.3, 0.28) | 0.69 |
↵3-150 Comparison of change between the groups (linear regression adjusted for baseline).
IQR, interquartile range.